Category: Financial Results
-
Lucid Diagnostics shares rise by 13% following first quarter results
The company boasted of over 3k sales of EsoGuard esophageal DNA tests, with $0.8 million in corresponding revenue, in Q1 2025.
-
DBV scores $306.9m lifeline to advance peanut allergy patch
The French company’s shares were up 54.7% at market open as it secured funding to develop and commercialize its Viaskin peanut patch.
-
AstraZeneca’s 2024 revenue surges to $54bn despite uncertainties in China
The British company’s revenue was up by 21% last year, which also saw a 4.6% rise in AstraZeneca’s stock following the release of financial results.
-
Lilly’s stock surges as diabetes products push 2024 revenue to $45 billion
Eli Lilly’s 2024 revenue was up by 32% from the previous year, with type 2 diabetes therapies namely Trulicity, Mounjaro, and Jardiance being the big earners.
-
Novo Nordisk’s shares climb as Wegovy demand and 2024 profits surge
The Danish company reported a 25% growth in yearly sales, raking in $40.3 billion in net sales in 2024.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.